Crinetics Pharmaceuticals Inc is a pioneering clinical-stage pharmaceutical company based in San Diego, California, dedicated to crafting innovative treatments for rare endocrine diseases and endocrine-related tumors. With a focus on oral, nonpeptide therapies, its flagship product, paltusotine, is advancing through clinical trials targeting conditions like acromegaly and carcinoid syndrome. Additionally, Crinetics is exploring treatments for diseases caused by excess ACTH, primary hyperparathyroidism, and other endocrine disorders, aiming to address unmet medical needs with novel therapeutics.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire…
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the…
